AI company proactively seeks regulation! Anthropic submits draft AI regulation bill to the US government, proposes setting a "lethal red line"
Anthropic submits draft AI regulation bill to US lawmakers, proposing to halt the release of models with imminent risks and requiring mandatory testing and independent review, setting up a confrontation with the Trump administration's laissez-faire approach.
Amid growing concerns over the potential risks of rapidly advancing artificial intelligence technology, Anthropic PBC has submitted its own draft bill to U.S. lawmakers, proposing a regulatory framework for AI safety and security.
According to Politico, which first reported the bill, the proposal suggests that if an AI model is determined to pose an imminent riskone that could cause more than 50 deaths or injuries, or result in losses exceeding $1 billionthe government could block the model's release. Politico reported that such threats must stem from the model creating or releasing biological weapons, AI escaping human control, or cyberattacks.
A company spokesperson said: "The bill represents the proposals outlined in Anthropic's 'Advanced AI Framework,' which we have been advocating to federal and state lawmakers since June."
The spokesperson stated that the bill would mandate AI developers to test their models and disclose test results to the public; it would also require AI companies to allow independent evaluation bodies to periodically review models.
The spokesperson said: "Our proposal also gives the federal government the ability to block or deter dangerous deployment of the most powerful models. We believe these are reasonable policies that Congress should act on."
The company declined to comment on the scope of its outreach regarding the proposal and the response received so far.
In recent months, a series of intrusions and hacking incidents involving AI models have intensified anxiety about the technology's potentially catastrophic risks, sparking calls for new safeguards from Washington to Silicon Valley, but so far, President Trump's administration has rejected calls for stronger regulation.
Related Articles

Title context: South Korea's largest biopharmaceutical M&A deal is about to closewhy is Samsung Biologics betting on the peptide CDMO track?
Text:
South Korea's largest biopharmaceutical M&A deal is about to closewhy is Samsung Biologics betting on the peptide CDMO track?

IMF warns that Japan may need to raise interest rates faster, adding further pressure to global bond markets?

AI Financing Costs Climb: Anthropic Plans to Offer Blackstone Over 10% Yield
Title context: South Korea's largest biopharmaceutical M&A deal is about to closewhy is Samsung Biologics betting on the peptide CDMO track?
Text:
South Korea's largest biopharmaceutical M&A deal is about to closewhy is Samsung Biologics betting on the peptide CDMO track?

IMF warns that Japan may need to raise interest rates faster, adding further pressure to global bond markets?

AI Financing Costs Climb: Anthropic Plans to Offer Blackstone Over 10% Yield






